494
Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
 increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Subject; children: Subject.Age; high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol: Treatment; acute lymphoblastic leukemia: Treatment.Disorder; lymphoblastic lymphoma: Treatment.Disorder; cytarabine: Treatment.Drug; high-dose: Treatment.Dosage
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Subject; children: Subject.Age; high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol: Treatment; acute lymphoblastic leukemia: Treatment.Disorder; lymphoblastic lymphoma: Treatment.Disorder; cytarabine: Treatment.Drug; high-dose: Treatment.Dosage